XORTX Therapeutics Inc (TSE:XRTX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
XORTX Therapeutics Inc. has announced that their study on the effects of xanthine oxidase activity in Polycystic Kidney Disease (PKD) will be presented at the American Society of Nephrology’s Kidney Week 2024. The study, which includes data from rats, mice, and human subjects, suggests that increased activity of this enzyme could be linked to the progression of PKD. The company anticipates sharing more detailed results in November.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
